Overview

In 2019, the Executive Guideline Steering Group (GSG) for the World Health Organization (WHO) maternal and perinatal health recommendations prioritized updating the then current WHO recommendations on antiplatelet agents for the prevention of pre-eclampsia. This decision was based on new evidence on the subject that had become available. The recommendation in this document thus supersedes the previous WHO recommendations on antiplatelet agents for the prevention of pre-eclampsia as published in the 2011 guidelines, WHO recommendations for the prevention and treatment of pre-eclampsia and eclampsia

Contents

• Acknowledgements
• Abbreviations
• Executive Summary
  • Introduction
  • Target audience
  • Guideline development methods
  • Recommendations
• 1. Introduction
  • Background
  • Rationale and objectives
  • Target audience
  • Scope of the recommendations
  • Persons affected by the recommendations
• 2. Methods
  • Contributors to the guidelines
  • Identification of priority questions and outcomes
  • Evidence identification and retrieval
  • Certainty assessment and grading of the evidence
  • Formulation of the recommendation
  • Management of declarations of interests
  • Decision-making during the GDG meetings
  • Document preparation
  • Peer review
• 3. Recommendations and supporting evidence
• 4. Dissemination, adaptation and implementation of the recommendations
  • Recommendation dissemination
  • Adaptation
  • Implementation considerations
• 5. Research implications
  • Research priorities
• 6. Applicability issues
  • Anticipated impact on the organization of care and resources
  • Monitoring and evaluating guideline implementation
• 7. Updating the recommendations
• References
• Annex 1. Participants in the guideline development process
• Annex 2. Priority outcomes used in decision-making
• Annex 3. Summary and management of declared interests from meeting participants
• Annex 4. Evidence to Decision framework
• References

Suggested citation:

WHO recommendations on antiplatelet agents for the prevention of pre-eclampsia. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.